Arterial Hypertension is a dedicated Open Access journal published by VIA MEDICA, with the ISSN 2449-6170 and E-ISSN 2449-6162, focusing on the multidisciplinary field of cardiology, endocrinology, and internal medicine. Established in Poland, this journal has been providing researchers and healthcare professionals with accessible, high-quality content since its inception in 1999. With a commitment to advancing knowledge in the management and treatment of arterial hypertension, it publishes significant research findings, clinical trials, and reviews that contribute to improved health outcomes. Though classified in Q4 across various relevant categories, the continuous improvement in its content ensures its relevance in an evolving medical landscape. Designed to facilitate collaboration and innovation, Arterial Hypertension serves as a crucial resource for anyone invested in cardiovascular health, encouraging open dialogue and dissemination of vital research within the scientific community.

Cardiovascular Therapeutics is a renowned Open Access journal, published by WILEY-HINDAWI, that has been at the forefront of advancing knowledge in the field of cardiology and cardiovascular medicine since its establishment. With a strong commitment to disseminating high-quality research, the journal has successfully positioned itself within the Q2 quartile in multiple categories, including Cardiology and Cardiovascular Medicine, Medicine (miscellaneous), and Pharmacology. The journal is indexed in Scopus, achieving impressive rankings, such as #95 out of 387 in Cardiology, and #87 out of 272 in Medical Pharmacology. Situated in the United Kingdom, Cardiovascular Therapeutics embraces an Open Access model since 2019, ensuring that groundbreaking research is accessible to researchers, practitioners, and students across the globe. The journal is dedicated to publishing original research articles, reviews, and clinical studies that contribute to the understanding and treatment of cardiovascular diseases, making it an essential resource for those invested in improving patient outcomes and advancing therapeutic strategies in this vital area of medicine.

Metabolic Syndrome and Related Disorders is an esteemed journal published by MARY ANN LIEBERT, INC, focusing on the multifaceted aspects of metabolic syndrome, including its interaction with chronic diseases such as diabetes, cardiovascular conditions, and obesity. Since its inception in 2003, this journal has established itself as a vital resource for researchers, healthcare professionals, and students dedicated to advancing knowledge in the fields of endocrinology, internal medicine, and metabolic disorders. With an impact factor reflective of its academic significance, Metabolic Syndrome and Related Disorders is recognized within the Q2 and Q3 quartiles in its respective categories, solidifying its reputation among scientific and clinical communities. Although it does not currently offer open access options, the journal remains committed to disseminating high-quality research and reviews that foster innovative solutions and improve patient outcomes. The journal's gradual convergence towards 2024 presents an exciting opportunity for continued exploration and dialogue about metabolic-related health challenges.

Clinical Hypertension is a premier journal dedicated to advancing the field of hypertension and cardiovascular health, published by SpringerNature. Since its transition to an Open Access model in 2014, the journal has opened doors for researchers globally to share their findings without barriers, aiming to foster collaboration and innovation in this vital area of medicine. With a current impact factor that positions it in the Q2 quartile for both Cardiology and Cardiovascular Medicine and Internal Medicine, Clinical Hypertension is recognized for its scholarly contributions, reflected in its Scopus rankings (Rank #100/387 in Cardiology and Rank #52/167 in Internal Medicine), which place it in the top percentiles of these competitive fields. Covering a diverse range of topics within hypertension research, it serves as an essential resource for clinicians, researchers, and students alike, promising to keep its audience informed of the latest developments and breakthroughs from its inception in 2017 through to 2024.

CARDIOVASCULAR RESEARCH, published by Oxford University Press, is a premier academic journal dedicated to the evolving field of cardiology and cardiovascular medicine. With a remarkable impact factor reflecting its significant contribution to the scientific community, this journal maintains a Q1 ranking in both Cardiology and Physiology categories, demonstrating its commitment to publishing high-quality research that influences clinical practices and healthcare outcomes. Established in 1967, the journal has consistently provided a platform for innovative studies and reviews, aiming to advance our understanding of cardiovascular physiology and pathology. Researchers, professionals, and students will find published articles crucial for their work, as the journal covers a broad spectrum of topics including molecular biology, genetics, and clinical studies. While currently not offering open access options, CARDIOVASCULAR RESEARCH remains accessible through institutional and individual subscriptions, ensuring that the latest findings are available to those in the cardiovascular science community.

Clinica e Investigacion en Arteriosclerosis is a premier academic journal dedicated to the field of cardiology and cardiovascular medicine, published by ELSEVIER. With its ISSN 0214-9168 and E-ISSN 1578-1879, the journal aims to disseminate high-quality research and innovations in the understanding and treatment of arterial diseases, contributing significantly to both clinical practices and pharmacological advancements. Established in 2007 and continuing into 2024, the journal has garnered recognition with a notable Q3 categorization in both Cardiology and Cardiovascular Medicine and Pharmacology (medical) for 2023, reflecting its impact in the academic community. Researchers and healthcare professionals utilizing this journal will find a diverse range of articles exploring novel therapeutic strategies and epidemiological data, making it an essential resource for advancing knowledge and practice in cardiovascular health. While it does not operate as an open-access journal, the findings published in Clinica e Investigacion en Arteriosclerosis are pivotal for understanding current trends and future directions in cardiovascular research.

Journal of Atherosclerosis and Thrombosis is a leading academic publication dedicated to advancing research in the fields of cardiovascular medicine, biochemistry, and internal medicine. Published by the Japan Atherosclerosis Society, this esteemed journal operates from its headquarters in Tokyo, Japan, and has been a vital resource in its area since its inception in 1994. With its robust impact in Cardiology and Cardiovascular Medicine, ranking in the top quartile (Q1) as of 2023, and a commendable standing in Internal Medicine and Biochemistry, the journal fosters an environment of innovation and discovery, showcasing significant studies and advancements that shape clinical practices and therapeutic approaches. Though not an open-access publication, it offers a wealth of insights to researchers, professionals, and students seeking to deepen their understanding of atherosclerosis and thrombosis. By continually featuring high-quality articles, the Journal of Atherosclerosis and Thrombosis plays an essential role in bridging the gap between research and practice, facilitating critical conversations that influence the future of cardiovascular health.

Kidney & Blood Pressure Research, published by KARGER, is a premier open-access journal dedicated to the evolving fields of nephrology and cardiovascular medicine. Since its inception in 1978 and with a forward-looking scope extending to 2024, this journal plays a vital role in disseminating innovative research and clinical findings related to kidney health and blood pressure regulation. With an impressive 2023 Impact Factor and ranked in the second quartile (Q2) in both cardiology and nephrology categories, it is recognized as a significant resource among its peers, including a Scopus rank of #23 in Nephrology and #128 in Cardiology. The journal's commitment to open access since 2013 further ensures that cutting-edge research is readily available to the global scientific community. Based in Switzerland, the journal not only fosters academic collaboration but also addresses critical health challenges related to kidney function and hypertension. It is a crucial platform for researchers, healthcare professionals, and students alike, encouraging the ongoing dialogue and advancement of knowledge in these critical areas of health.

Integrated Blood Pressure Control is a distinguished Open Access journal published by DOVE MEDICAL PRESS LTD in New Zealand, dedicated to advancing the field of cardiology and cardiovascular medicine as well as internal medicine. With its established timeline from 2009 to 2024, this journal has earned a commendable Q2 ranking in both its categories for 2023, reflecting its significant contribution to clinical research and practice. With an ISSN of 1178-7104, it provides a platform for high-quality, peer-reviewed articles that address the complexities of blood pressure management, aiming to improve patient outcomes and foster discussions among healthcare professionals. The journal's open-access model, implemented since 2008, ensures that research findings are readily available to all, promoting greater accessibility and dissemination of knowledge in this critical area of health. Researchers, professionals, and students alike are encouraged to engage with the latest findings and innovative practices published within this journal, which plays an essential role in shaping the future of blood pressure control and related medical fields.

BLOOD PRESSURE is a distinguished journal published by Taylor & Francis Ltd in the field of cardiology and internal medicine, with an ISSN of 0803-7051 and E-ISSN of 1651-1999. Since its inception in 1992, it has become a vital source of research and clinical information, dedicated to advancing our understanding of blood pressure-related health issues. With a notable categorization of Q3 in Cardiology and Cardiovascular Medicine and Q2 in Internal Medicine as of 2023, this journal exemplifies a commitment to evidence-based findings that impact clinical practice and patient care. The journal facilitates a platform for original research, reviews, and case studies, aiming to bridge the gap between researchers and practitioners. Although it does not currently offer open access, BLOOD PRESSURE remains an essential resource for professionals and students alike, striving to enhance health outcomes through dedication to innovative cardiovascular research.